Featured Research

from universities, journals, and other organizations

Blood clotting finding may lead to new treatments

Date:
February 11, 2010
Source:
Imperial College London
Summary:
A key protein that causes the blood to clot is produced by blood vessels in the lungs and not just the liver, according to new research. The findings may ultimately help scientists to develop better treatments for conditions where the blood's ability to clot is impaired, including deep vein thrombosis, where dangerous blood clots form inside the body, and haemophilia A, where the blood cannot clot sufficiently well.

A key protein that causes the blood to clot is produced by blood vessels in the lungs and not just the liver, according to new research published in the journal PLoS ONE, led by scientists at Imperial College London.

The findings may ultimately help scientists to develop better treatments for conditions where the blood's ability to clot is impaired, including deep vein thrombosis, where dangerous blood clots form inside the body, and haemophilia A, where the blood cannot clot sufficiently well.

It has long been known that an agent called factor VIII plays a key role in enabling the blood to clot. Too much factor VIII puts people at risk of excessive clots. Low levels of factor VIII cause bleeding in people with haemophilia A and factor VIII replacement is used to treat this.

Prior to recent research it had been believed that most factor VIII was produced by the liver. Therapeutic options for patients with haemophilia have included replacing liver cells, for example through transplantation.

Dr Claire Shovlin, the lead author of the study from the National Heart and Lung Institute at Imperial College London, said: "Our study suggests that the blood vessels in the lung are playing a crucial role in altering how blood clots form in the body. There are a huge number of these blood vessels -- they cover an area equivalent in size to a squash court, effectively 20 times the surface area of all other blood vessels combined.

"This means it's really important for us to understand exactly how the behaviour of the lung blood vessels might be affecting diseases where blood clotting is a factor. Further research on how the lungs modify the clotting potential of the blood flowing through them could open up new avenues for treatments," added Dr Shovlin.

In 2006, researchers from the University of Leuven in Belgium published a study in the journal Blood looking at donated lung tissue. The researchers passed fluid through the tissue and found that in three of the four lung samples studied, the levels of factor VIII increased in the fluid after passing through the lungs. They also provided evidence that some lung blood vessels could produce factor VIII in cell culture.

The researchers behind the study have confirmed that the blood vessels in the lungs should be an important site for regulating the formation of clots, both in the lungs themselves and also, potentially, in the rest of the body. They used different microscopic and biochemical techniques to look at samples of lung tissue and blood samples in minute detail.

Tissue and blood samples for the work leading up to this study were donated by patients from Imperial College Healthcare NHS Trust, with tissue processed through the Hammersmith Hospital Tissue Bank.

The team found that factor VIII could be seen in the lung tissue and was present on the surface of blood vessel cells in the lungs. They also found that factor VIII localises in the lungs with a protein called von Willebrand factor, which protects factor VIII from degradation. The work also showed that how the factor VIII gene may be decoded is much more complicated than previously thought. This could potentially alter how scientists approach the treatment of the many conditions where blood clotting is a factor.

The researchers hope that ultimately new drugs can be developed that target production of factor VIII in the lungs, to improve the body's ability to ensure that the blood clots properly. By targeting the lungs, the researchers think it may be possible to make more effective drugs that produce fewer side effects than current treatments.


Story Source:

The above story is based on materials provided by Imperial College London. Note: Materials may be edited for content and length.


Cite This Page:

Imperial College London. "Blood clotting finding may lead to new treatments." ScienceDaily. ScienceDaily, 11 February 2010. <www.sciencedaily.com/releases/2010/02/100210210211.htm>.
Imperial College London. (2010, February 11). Blood clotting finding may lead to new treatments. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/02/100210210211.htm
Imperial College London. "Blood clotting finding may lead to new treatments." ScienceDaily. www.sciencedaily.com/releases/2010/02/100210210211.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins